We have shown that nocturnal asthma (NA) is associated with increased parenchymal inflammation; however, whether the inflammation results in a functional change in the distal lung is not known. Therefore, we studied 10 subjects with NA, 4 subjects with non-nocturnal asthma (NNA) and 4 nonasthmatic controls (C). They underwent lung function testing followed by esophageal balloon placement and bronchoscopy in a random order at 4 pm and 4 am, respectively. The bronchoscope was wedged in the anterior segment of the right lower lobe followed by insertion of a size 5 French catheter. Warm, saturated air at flows ranging from 100 ml/min-1000 ml/min exited the catheter through one lumen and pressure was measured through the second lumen. Resistance (Rp) was defined as the pressure/flow averaged over three or more flow levels for each subject. Flow was stopped at functional residual capacity and the pressure was allowed to decay for 10 seconds; the time to decay by 63% (1/e) of the total was defined at the time constant (TC). Compliance (Compl) was calculated as TC/Rp. The Rp was significantly higher in NA (p=0.002 at 4 am and 0.003 at 4 pm) and compliance was significantly lower (p=0.02 at 4 am and 0.003 at 4 pm) than NNA and C (see table). Group Rp 4 am Rp 4pm Compl 4 am Compl 4 pm (cm H20/ml/min) (cm H20/ml/min) (ml/cm H20) (ml/cm H20) C 0.009 [0.006-0.011] 0.011 [0.001-0.013] 454 [205-705] 280 [141-522] NNA 0.035 [0.022-0.048] 0.035 [0.022-0.048] 57 [21-154] 71 [32-126] NA 0.124 [0.055-0.165] 0.113 [0.059-0.200] 10 [5.4-14.6] 8 [4-19] In addition, when related to whole lung function, the residual volume correlated with the Rp at both 4 am and 4 pm (4 am: r=0.60, p=0.03; 4 pm: 0.71, p=0.004). On the other hand, FEV1 and FVC did not correlate with the Rp at either time point. We conclude that these findings are consistent with the hypothesis that, in asthma, increased inflammatory activity causes progressive parenchymal dysfunction.

Project Start
1998-12-01
Project End
1999-11-30
Budget Start
1998-10-01
Budget End
1999-09-30
Support Year
38
Fiscal Year
1999
Total Cost
Indirect Cost
Name
University of Colorado Denver
Department
Type
DUNS #
065391526
City
Aurora
State
CO
Country
United States
Zip Code
80045
Venuto, Charles S; Lim, Jihoon; Messing, Susan et al. (2018) Inflammation investigated as a source of pharmacokinetic variability of atazanavir in AIDS Clinical Trials Group protocol A5224s. Antivir Ther 23:345-351
Li, Binglan; Verma, Shefali S; Veturi, Yogasudha C et al. (2018) Evaluation of PrediXcan for prioritizing GWAS associations and predicting gene expression. Pac Symp Biocomput 23:448-459
Hayden, Kathleen M; Baker, Laura D; Bray, George et al. (2018) Long-term impact of intensive lifestyle intervention on cognitive function assessed with the National Institutes of Health Toolbox: The Look AHEAD study. Alzheimers Dement (Amst) 10:41-48
Shah, V N; Sippl, R; Joshee, P et al. (2018) Trabecular bone quality is lower in adults with type 1 diabetes and is negatively associated with insulin resistance. Osteoporos Int 29:733-739
Jensen, Thomas; Bjornstad, Petter; Johnson, Richard J et al. (2018) Copeptin and Estimated Insulin Sensitivity in Adults With and Without Type 1 Diabetes: The CACTI Study. Can J Diabetes :
Dad, Taimur; Abebe, Kaleab Z; Bae, K Ty et al. (2018) Longitudinal Assessment of Left Ventricular Mass in Autosomal Dominant Polycystic Kidney Disease. Kidney Int Rep 3:619-624
Millstein, Richard J; Pyle, Laura L; Bergman, Bryan C et al. (2018) Sex-specific differences in insulin resistance in type 1 diabetes: The CACTI cohort. J Diabetes Complications 32:418-423
Martin, Maureen P; Naranbhai, Vivek; Shea, Patrick R et al. (2018) Killer cell immunoglobulin-like receptor 3DL1 variation modifies HLA-B*57 protection against HIV-1. J Clin Invest 128:1903-1912
Nowak, Kristen L; You, Zhiying; Gitomer, Berenice et al. (2018) Overweight and Obesity Are Predictors of Progression in Early Autosomal Dominant Polycystic Kidney Disease. J Am Soc Nephrol 29:571-578
Haas, David W; Bradford, Yuki; Verma, Anurag et al. (2018) Brain neurotransmitter transporter/receptor genomics and efavirenz central nervous system adverse events. Pharmacogenet Genomics 28:179-187

Showing the most recent 10 out of 1065 publications